PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 104 filers reported holding PARATEK PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,469 | -29.6% | 4,292 | -18.9% | 0.00% | – |
| Q1 2023 | $13,456 | +34.2% | 5,292 | -0.3% | 0.00% | – |
| Q4 2022 | $10,030 | -22.8% | 5,308 | +10.8% | 0.00% | – |
| Q3 2022 | $13,000 | +44.4% | 4,792 | 0.0% | 0.00% | – |
| Q2 2022 | $9,000 | -35.7% | 4,792 | 0.0% | 0.00% | – |
| Q1 2022 | $14,000 | -39.1% | 4,792 | -9.4% | 0.00% | – |
| Q4 2021 | $23,000 | -57.4% | 5,292 | -53.2% | 0.00% | – |
| Q3 2021 | $54,000 | -41.9% | 11,310 | -16.2% | 0.00% | – |
| Q2 2021 | $93,000 | -22.5% | 13,490 | -19.8% | 0.00% | – |
| Q1 2021 | $120,000 | +16.5% | 16,820 | +2.4% | 0.00% | – |
| Q4 2020 | $103,000 | +145.2% | 16,420 | +109.7% | 0.00% | – |
| Q3 2020 | $42,000 | +10.5% | 7,830 | +9.8% | 0.00% | – |
| Q2 2020 | $38,000 | +65.2% | 7,130 | 0.0% | 0.00% | – |
| Q1 2020 | $23,000 | – | 7,130 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |